

Minakem invests in Chromatography

Minakem, Minafin Group's arm dedicated to the chemical development and manufacturing for the pharmaceutical industry, and the supply of associated services for the drug products, today announces that it has finalized the first phase of the commissioning of preparative high pressure chromatography capability in its Belgian facility specialized on the manufacturing of High Potent Products. This first phase consists in the installation of a 50mm column Hipersep® Prep-HPLC system that will be followed by a 300mm column in the course of 2018. This will support the development and manufacturing of complex pharmaceutical ingredients requiring a very high degree of purity.

"This investment is part of Minafin's commitment to a 10 M Euro investment plan in line with Minakem's global strategy to become a fully integrated partner of the pharmaceutical industry for the supply of their High Potent API. This technology can be operated under high containment and will be a key differentiator for the company allowing purification of high potent compounds such as ADC toxins and other complex mixtures, from clinical development up to commercial supply. It will contribute to expand our offering in products that are often hemi-synthetic and difficult to purify by classical crystallization processes", says Frédéric Gauchet, President, Minafin Group

The Belgian facility located in Louvain-la-Neuve, Belgium, has 6 production lines equipped with glass line, stainless steel, hastelloy jacketed reactors ranging from 5L to 1600L in size, several isolation equipment for batch sides ranging from 100g to 100kg, designed to ensure with a triple level of containment a safe handling of high potent compounds.

About Minafin:

with a long history of providing superior service and innovation, Minafin group is at the core a manufacturer of fine chemicals, pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Today the group is counting on 6 manufacturing sites, 2 in US, 2 in France, 1 in Germany and 1 in Belgium for a total of 780 employees developing a turnover of 159 M EUR in 2016. The 4 European sites are all FDA approved and have a long distinguished history providing clients with cGMP intermediates, complex fine chemicals, APIs, HAPI and generics, contract services for the pharmaceutical and life science industries. These facilities provide a full range of complementary technologies and services to the pharmaceutical industry for small, medium and large volumes of complex, regulated intermediates and APIs.

More information: www.minafin.com +  [minafin-group](https://www.linkedin.com/company/minafin-group) +  [@Minafin_Group](https://twitter.com/Minafin_Group)

MINAFIN s.p.r.l.

Fonds Jean Pâques 8 | Parc Fleming | B-1435 Mont-Saint-Guibert | Belgique
Tél: +32 10 23 85 73 | www.minafin.com

Capital social de 2 832 500 EUR |
TVA BE 0660 622 953 |